CTLA4 and melanoma: In the case of the triple wild-type melanoma, the only recommended therapy option is immunotherapy in the form of anti-PD-1 (programmed cell death protein 1) and/or anti-CTLA-4 (cytotoxic T cell antigen 4) antibodies [49].